Personalized medicine in oncology / / Ari Vanderwalde, editor.
Nowhere is the explosion in comprehensive genomic testing more evident than in oncology. Multiple consensus guidelines now recommend molecular testing as the standard of care for most metastatic tumors. To aid in the advancement of this rapidly changing field, we intend this Special Issue of JPM to...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | Basel : : MDPI - Multidisciplinary Digital Publishing Institute,, 2022. |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 online resource (174 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993603216104498 |
---|---|
ctrlnum |
(CKB)5400000000042977 (NjHacI)995400000000042977 (EXLCZ)995400000000042977 |
collection |
bib_alma |
record_format |
marc |
spelling |
Personalized medicine in oncology / Ari Vanderwalde, editor. Basel : MDPI - Multidisciplinary Digital Publishing Institute, 2022. 1 online resource (174 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on print version record. Nowhere is the explosion in comprehensive genomic testing more evident than in oncology. Multiple consensus guidelines now recommend molecular testing as the standard of care for most metastatic tumors. To aid in the advancement of this rapidly changing field, we intend this Special Issue of JPM to focus on technical developments in the genomic profiling of cancer, detail promising somatic alterations that either are, or have a high likelihood of being, relevant in the near future, and to address issues related to the pricing and value of these tests.The last few years have seen the cost of molecular testing decrease by orders of magnitude. In 2018, we saw the first "site-agnostic" drug approvals in cancer (for microsatellite unstable cancer (PD-1 inhibitors) and NTRK-fusions (TRK inhibitors)). Research on targetable mutations, determination of genetic "signatures" that can use multiple individual genes/pathways, development of targeted therapy, and insight into the value of new technology remains at the cutting edge of research in this field. We are soliciting papers that present new technologies to assess predictive biomarkers in cancer, original research (pre-clinical or clinical) that demonstrates promise for particular targeted therapies in cancer, and articles that explore the clinical and financial impacts of this paradigmatic shift in cancer diagnostics and treatment. Oncology. Oncology Research. 3-0365-2821-0 Vanderwalde, Ari, editor. |
language |
English |
format |
eBook |
author2 |
Vanderwalde, Ari, |
author_facet |
Vanderwalde, Ari, |
author2_variant |
a v av |
author2_role |
TeilnehmendeR |
title |
Personalized medicine in oncology / |
spellingShingle |
Personalized medicine in oncology / |
title_full |
Personalized medicine in oncology / Ari Vanderwalde, editor. |
title_fullStr |
Personalized medicine in oncology / Ari Vanderwalde, editor. |
title_full_unstemmed |
Personalized medicine in oncology / Ari Vanderwalde, editor. |
title_auth |
Personalized medicine in oncology / |
title_new |
Personalized medicine in oncology / |
title_sort |
personalized medicine in oncology / |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute, |
publishDate |
2022 |
physical |
1 online resource (174 pages) |
isbn |
3-0365-2821-0 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC261 |
callnumber-sort |
RC 3261 P477 42022 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
616 - Diseases |
dewey-full |
616.994 |
dewey-sort |
3616.994 |
dewey-raw |
616.994 |
dewey-search |
616.994 |
work_keys_str_mv |
AT vanderwaldeari personalizedmedicineinoncology |
status_str |
n |
ids_txt_mv |
(CKB)5400000000042977 (NjHacI)995400000000042977 (EXLCZ)995400000000042977 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Personalized medicine in oncology / |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796653209011355648 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02301nam a2200289 i 4500</leader><controlfield tag="001">993603216104498</controlfield><controlfield tag="005">20230625171822.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230625s2022 enk o 000 0 eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000042977</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995400000000042977</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000042977</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC261</subfield><subfield code="b">.P477 2022</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Personalized medicine in oncology /</subfield><subfield code="c">Ari Vanderwalde, editor.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel :</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (174 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on print version record.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nowhere is the explosion in comprehensive genomic testing more evident than in oncology. Multiple consensus guidelines now recommend molecular testing as the standard of care for most metastatic tumors. To aid in the advancement of this rapidly changing field, we intend this Special Issue of JPM to focus on technical developments in the genomic profiling of cancer, detail promising somatic alterations that either are, or have a high likelihood of being, relevant in the near future, and to address issues related to the pricing and value of these tests.The last few years have seen the cost of molecular testing decrease by orders of magnitude. In 2018, we saw the first "site-agnostic" drug approvals in cancer (for microsatellite unstable cancer (PD-1 inhibitors) and NTRK-fusions (TRK inhibitors)). Research on targetable mutations, determination of genetic "signatures" that can use multiple individual genes/pathways, development of targeted therapy, and insight into the value of new technology remains at the cutting edge of research in this field. We are soliciting papers that present new technologies to assess predictive biomarkers in cancer, original research (pre-clinical or clinical) that demonstrates promise for particular targeted therapies in cancer, and articles that explore the clinical and financial impacts of this paradigmatic shift in cancer diagnostics and treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Oncology.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Oncology</subfield><subfield code="x">Research.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2821-0</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vanderwalde, Ari,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-07-06 03:34:12 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338050090004498&Force_direct=true</subfield><subfield code="Z">5338050090004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338050090004498</subfield></datafield></record></collection> |